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The c-MYC proto-oncogene represents a nodal 
point of gene regulation, as it integrates numerous 
mitogenic incoming signals and converts them into 
enhanced synthesis of the c-MYC transcription factor, 
which orchestrates the expression of hundreds of genes 
[1]. Deregulation of c-MYC , as it is found in ~50% of 
all human cancers, not only induces cellular proliferation 
and growth but also leads to activation of the p53 tumor 
suppressor protein [2], which mediates apoptosis and/or 
senescence. This intrinsic fail-safe mechanism prevents 
expansion of cells harboring dangerous oncogenic 
mutations. The necessity to bypass this barrier is thought 
to explain why p53 is frequently mutated in human cancers 
of all types. However, ectopic expression of c-MYC may 
immortalize certain primary cells in the presence of wild-
type p53, suggesting that c-MYC circumvents the action 
of p53 by alternative mechanisms. We hypothesized that 
c-MYC may activate a factor, which abrogates or down-
regulates p53 function directly. An attractive candidate for 
this function was SIRT1, an NAD+-dependent deacetylase, 
which has been shown to inhibit the function of p53 [3]. 
Recently, four papers showed that c-MYC and SIRT1 
regulate each other via feedback loops [4-7]. The three 
more recent publications suggest the existence of a positive 
feedback loop between c-MYC and SIRT1 [4-6], whereas 
a study published earlier entertains a negative feedback 
[7]. The positive feedback suggests an oncogenic role of 
SIRT1, whereas the negative feedback implies a tumor 
suppressive activity of SIRT1. In our hands activation of 
conditional c-MYC alleles resulted in a robust increase 
in SIRT1 protein levels and activity. This was mediated 
on one hand via the direct induction of the NAMPT gene, 
which encodes nicotinamide phosphoribosyltransferase, 
the rate limiting enzyme of the NAD+ salvage pathway. 
The resulting increased NAD+ levels are known to 
mediate the activation of SIRT1 [8]. A second mode of 
SIRT1 activation was through sequestration of the SIRT1 
inhibitor DBC1 (deleted in breast cancer 1) by c-MYC. 
In c-MYC-immortalized cells the increased levels and 
enzymatic activity of SIRT1 were necessary to prevent 
senescence and c-MYC-induced apoptosis. Furthermore, 
c-MYC is bound and deacetylated by SIRT1 which 
resulted in reduced K48- and increased K63-ubiquitin 
linkage, and ultimately increased c-MYC stability and 
activity. In cancer cells deregulation of this reciprocal 
activation between c-MYC and SIRT1 presumably 
contributes to evasion of senescence and apoptosis [6]. 
Increased expression of SIRT1 mRNA in cells with 
elevated c-MYC or N-MYC levels suggested that c-MYC 
may transactivate the SIRT1 gene [5, 7]. Although we 
could not detect an increase in SIRT1 mRNA after c-MYC 
activation [6], a concomitant induction of SIRT1 mRNA 
and post-transcriptional activation of the SIRT1 enzyme 
by c-MYC, as described above, may act synergistically. 
In the three studies describing a positive feedback, this 
involves a direct physical interaction between c-MYC 
and SIRT1, leading to increased c-MYC function [4-
6]. Only Yuan et al. observed that the interaction with 
SIRT1 reduced c-MYC stability and inhibited c-MYC 
functions, such as transformation and transactivation [7]. 
The region of MYC interacting with SIRT1 was reported 
to be either the C-terminus of c-MYC [4] or MYC-Box 
I within the N-terminus of N-MYC [5]. Although three 
studies document deacetylation of c-MYC as a result of 
the SIRT1/c-MYC interaction, there are considerable 
discrepancies with respect to the functional consequences 
of c-MYC deacetylation. In agreement with our own 
observations obtained for c-MYC, Marshall et al. report 
that the N-MYC protein is stabilized in the presence of 
SIRT1. However, this is mediated indirectly through a 
novel transcriptional repressor complex consisting of 
N-MYC and SIRT1, which down-regulates expression of 
mitogen-activated protein kinase phosphatase 3 (MKP3) 
and thereby increases ERK-mediated phosphorylation 
of N-MYC at serine 62. Mao et al. did not observe 
significant effects of SIRT1 on c-MYC protein levels. 
Furthermore, they found that SIRT1 binds to the 
C-terminus of c-MYC, which mediates heterodimerization 
with MAX. Interestingly, SIRT1 expression increased 
the c-MYC/MAX association and also enhanced 
c-MYC transcriptional activity. Taken together, the 
majority of the reported analyses (3 of 4) describe a 
positive feedback between c-MYC and SIRT1. Multiple 
mechanisms of c-MYC activation seem to be involved 
in this feedback. Indeed, the SIRT1-mediated increase in 
c-MYC expression and function by enhanced ubiquitin 
63 linkage, serine 62 phosphorylation and c-MYC/
MAX heterodimerization may occur in parallel and act 
synergistically. In conjunction with the inactivation of 
p53 and/or other tumor suppressive SIRT1 substrates, 
SIRT1 therefore seems to act pro-tumorigenic at least in 
the context of cells and tumors, which display alterations 
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